News

Cisco today announced it will host Splunk's annual .conf25 user conference from September 8–11, 2025, at the Thomas Michael ...
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.
“Onco360 is grateful for the opportunity to partner with the Regeneron team and become a specialty pharmacy provider for Lynozyfic,” said Benito Fernandez, Chief Commercial Officer.“We are proud to ...
The FDA issued a Complete Response Letter for Regeneron’s biologics license application for odronextamab, a bispecific antibody targeting CD20 and CD3 for the treatment of relapsed or refractory ...
"This could be a huge step." Teen scientist makes stunning breakthrough that could slash costs of lifesaving drugs: 'I cannot ...
During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...
RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.
The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...